GLUE · Monte Rosa Therapeutics, Inc.
AI read · Good for GLUE
The AI's read
Changes across several inflammation markers and other heart-related blood measures give Monte Rosa a reason to keep testing MRT-8102. The company plans 3 Phase 2 studies to examine the drug further. Still, 108 people took it for only 4 weeks. The report does not show whether the drug prevents heart attacks or improves patients’ health.